News
Resources
Blog
Sites
ICYMI: PhRMA kicks off the year at the 2023 J.P. Morgan Health Care Conference
By Katie Koziara | January 19, 2023
This January, PhRMA joined health care leaders, investors, R&D experts and members of the media at the 2023 J.P. Morgan Health Care Conference in San Francisco, CA. During this week, we discussed...
Read More
340B program continues to drive shift in care to more expensive hospital settings
By Nicole Longo | December 15, 2022
Yet another study highlights the unintended consequences of the 340B program, which is increasing costs for patients and the health care system as a whole. In this case, the Berkeley Research Group...
Read More
The 340B program is interfering with the U.S. biosimilars market and impacting patient costs
By Nicole Longo | November 21, 2022
Research has shown that 340B hospitals are more likely to prescribe more expensive medicines and significantly mark up the price of medicines. For example, 340B hospitals received nearly five times...
Read More
Three ways 340B is failing vulnerable patients
By Nicole Longo | October 20, 2022
The 340B Drug Pricing Program is 30 years old this year, but as The New York Times recently spelled out, the program has become a profit engine for large health systems over the years instead of a...
Read More
If patients aren’t benefiting from the 340B program, who is?
By Nicole Longo | October 6, 2022
The 340B Drug Pricing Program was designed to help vulnerable patients improve access to their medicines through manufacturer discounts to specific safety-net, non-profit hospitals and federally...
Read More
New data: The 340B program is driving up costs for patients and our health care system
By Nicole Longo | September 15, 2022
Guess what? The 340B program grew, yet again, hitting a whopping $43.9 billion in sales at the discounted 340B price in 2021. But there has not been evidence of corresponding growth in care provided...
Read More
Word of the Month: 340B covered entity
By Nicole Longo | August 29, 2022
What is a 340B covered entity?
Read More
340B program remains second largest federal drug program, yet little solid evidence of benefits to patient
By Nicole Longo | June 30, 2022
Over the three decades since Congress created the 340B drug pricing program, we’ve seen massive growth in its size. As a program meant to serve vulnerable patients, this sounds great, right? The...
Read More
Study after study after study: Contract pharmacy expansion not aligned in communities 340B is meant to serve
By Nicole Longo | June 24, 2022
Evidence continues to show that 340B hospitals and their contract pharmacies are often not helping patients access their medicines, especially patients in socioeconomically disadvantaged areas....
Read More
The 340B program was created to support safety-net clinics and qualifying hospitals by establishing a discounted medicine program funded by biopharmaceutical manufacturers to help vulnerable patients...
Read More
Medicare Monday (100)
340B Spotlight (46)
Cost & Consequence (0)
